Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV07050101

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2021

            Details:

            Expanded trial analysis is expected to allow for collection of relevant efficacy data which includes the important group of approximately 270 participants above the age of 60, treated with 12µg of CVnCoV.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV07050101

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 12, 2021

            Details:

            Over the course of the rolling submission process, EMA will assess CVnCoV’s compliance with standards for vaccine efficacy, safety, and pharmaceutical quality on the basis of individually submitted data packages as a prerequisite for a formal market authorization application.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rezafungin

            Therapeutic Area: Infections and Infectious Diseases Product Name: CD101

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Cidara Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 26, 2021

            Details:

            Rezafungin is a novel, once-weekly echinocandin, currently in Phase 3 clinical trials for both the treatment of invasive candidiasis and prophylaxis against severe invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CV07050101

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: CureVac

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 07, 2021

            Details:

            Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: University Medical Center

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 21, 2020

            Details:

            The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 µg. The trial follows an epidemiological, non-interventional study conducted with healthcare workers from the University Hospital in Mainz.